Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
Cash Flow Performance
Trending higher, above historical average, strong compound growth.
Left:
||||
Free cash flow yield
Latest
-8.49%
↑ 84% above average
Average (8y)
-52.21%
Historical baseline
Range
High:0.90%
Low:-267.23%
CAGR
+96.4%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | -8.49% | +96.8% |
| 2023 | -267.23% | -91.5% |
| 2022 | -139.57% | -161.3% |
| 2021 | -53.41% | -3179.9% |
| 2020 | -1.63% | -391.9% |
| 2019 | -0.33% | -136.7% |
| 2018 | 0.90% | +828.5% |
| 2017 | -0.12% | -222.9% |
| 2016 | -0.04% | - |